NextCure to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 06 2020 - 04:10PM
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical
company committed to discovering and developing novel,
first-in-class immunomedicines to treat cancer and other
immune-related diseases, today announced that the company will
present at the 38th Annual J.P. Morgan Healthcare Conference being
held January 13-16, 2020, in San Francisco, California.
NextCure’s President and Chief Executive Officer, Michael
Richman, will present at 10:00 am (PST) on January 16, 2020. A live
audio webcast will be available through the Investors section of
the company’s website at www.nextcure.com. A replay of the webcast
will be available approximately two hours after the event and
archived on the website for 30 days.
About NextCure, Inc.NextCure is a
clinical-stage biopharmaceutical company committed to discovering
and developing novel, first-in-class immunomedicines to treat
cancer and other immune-related diseases. Through our proprietary
FIND-IO™ platform, we study various immune cells to discover and
understand targets and structural components of immune cells and
their functional impact in order to develop immunomedicines. Our
initial focus is to bring hope and new treatments to patients who
do not respond to current cancer therapies, patients whose cancer
progresses despite treatment and patients with cancer types not
adequately addressed by available therapies.
http://www.nextcure.com
Cautionary Statement Regarding Forward-Looking
Statements Statements made in this press release that are
not historical facts are forward-looking statements. Words such as
“will,” “expects,” “believes,” “intends,” “hope,” “forward” and
similar expressions are intended to identify forward-looking
statements. Examples of forward-looking statements in this press
release include, among others, statements about NextCure’s plans,
objectives and intentions with respect to the discovery of
immunomedicine targets and the discovery and development of
immunomedicines. Forward-looking statements involve substantial
risks and uncertainties that could cause actual results to differ
materially from those projected in any forward-looking statement.
Such risks and uncertainties include, among others: our limited
operating history and no products approved for commercial sale; our
history of significant losses; our need to obtain additional
financing; risks related to clinical development, marketing
approval and commercialization; and the unproven approach to the
discovery and development of product candidates based on our
FIND-IO platform. More detailed information on these and additional
factors that could affect NextCure’s actual results are described
in NextCure’s filings with the Securities and Exchange
Commission (the “SEC”), including in the Risk Factors section
and throughout NextCure’s Form 10-Q filed with
the SEC on November 12, 2019. You should not place
undue reliance on any forward-looking statements. NextCure assumes
no obligation to update any forward-looking statements, even if
expectations change.
Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com
NextCure (NASDAQ:NXTC)
Historical Stock Chart
From Feb 2024 to Mar 2024
NextCure (NASDAQ:NXTC)
Historical Stock Chart
From Mar 2023 to Mar 2024